Category Archives: Insulin Delivery

Medtronic to Spin Off Diabetes Business and CY Q1 ’25 (FY Q4 ’25) Earnings; Akero Acquisition Rumor 

Two cardiometabolic-related news items have been observed: Medtronic announced plans to spin off its diabetes business (press release; slides) and hosted its CY Q1 ’25 (FY Q4 ’25) earnings call (press release; slides); and Akero Therapeutics has reportedly received an acquisition proposal from an undisclosed strategic buyer (view article). Below, FENIX provides highlights and insights for the respective news items, including thoughts on what the Medtronic diabetes spinoff means for the rest of the market.

This content is for Read Less members only.
Register
Already a member? Log in here

Noom Offers Lower-Dose Wegovy; Tandem’s Mobi Receives CE Mark; Ascletis Ph1 Obesity Study 

Three cardiometabolic-related news items have been observed: Noom is offering lower doses of compounded Wegovy (view article); Tandem Diabetes Care’s Mobi insulin pump received CE Mark (view 8-K filing); and Ascletis Pharma announced dosing the first patient in its Ph1 ASC47 (THR-β) obesity study (view press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo’s CEO Steps Down; Abbott Invests in Senseonics; Cellarity Hires Ex-Scholar Rock CFO 

Three cardiometabolic-related news items have been observed: Novo Nordisk announced its current CEO, Lars Fruergaard Jørgensen, will step down amid an ongoing search for a successor (view press release); Abbott has invested in Senseonics (view press release); and Flagship’s company, Cellarity, appoints new CEO (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Partners with Septerna for Obesity Drug Development; GSK Acquires MASH Asset from Boston Pharma; Sernova Interim Cell Pouch Results; Found Integrates with LillyDirect and NovoCare; Cytokinetics Ph3 HCM Results; Lexicon, Fractyl, and Scholar Rock Q1 ’25 Earnings 

A series of cardiometabolic-related news items has been observed from: Novo Nordisk/Septerna, GSK/Boston Pharmaceuticals, Sernova Biotherapeutics, Found, Cytokinetics, Lexicon Pharmaceuticals, Fractyl Health, and Scholar Rock. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Insulet, Senseonics, Skye, and Biocon Q1 ‘25 Earnings; Zealand and Roche Make it Official; Akero Presents MASH Data at EASL 2025; Lilly Initiates New Ph3 Tirzepatide Study in T1DM 

A series of cardiometabolic-related news items has been observed from Insulet, Senseonics, Zealand Pharma, Akero Therapeutics, Lilly, Skye Bioscience, and Biocon. Below, FENIX provides highlights and insights for the respective news items.  

This content is for Read Less members only.
Register
Already a member? Log in here

Beta Bionics Q1 ‘25 Earnings; MetaVia Presents MASH data at EASL 2025

Two cardiometabolic news items have been observed: Beta Bionics hosted its Q1 ‘25 earnings call (press release; slides); and MetaVia announced full results from its Ph2 DA-1241 study in MASH (press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Q1 ‘25 Earnings

Novo Nordisk hosted its Q1 ’25 earnings call (press release; slides) and provided updates across its CVRM portfolio and Novo’s near-term obesity pipeline. Of note, Novo lowered its FY 2025 guidance due to reduced GLP-1RA market penetration as a result of compounding. Below, FENIX provides highlights and insights from the Q1 ’25 earnings call.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Partners with Telehealth Providers; AstraZeneca, Pfizer, Novartis, and Regeneron Q1 ’25 Earnings; Abbott and Epic CGM Integration; Eversense 365 to Integrate with twiist AID System

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Pfizer, Novartis, Regeneron Pharmaceuticals, Abbott, and Sequel Med Tech/Senseonics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here